Screener
Cogent Biosciences, Inc. COGT Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The source filing: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:21 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-205170
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $241,208 | $312,012 |
| Short-term marketable securities | 625,170 | 588,753 |
| Prepaid expenses and other current assets | 11,425 | 9,590 |
| Total current assets | 877,803 | 910,355 |
| Operating lease, right-of-use assets | 17,549 | 18,078 |
| Property and equipment, net | 5,298 | 5,457 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Cogent Biosciences, Inc.'s short-term investments?
- Cogent Biosciences, Inc. (COGT) reported short-term investments of $625.17M in Q1 2026.
- How has Cogent Biosciences, Inc.'s short-term investments changed year-over-year?
- Cogent Biosciences, Inc.'s short-term investments increased by 422.5% year-over-year, from $119.66M to $625.17M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Cogent Biosciences, Inc.'s short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude